38216-61-4

Upstream product

• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 104-88-1 4-chlorobenzaldehyde 
• 52923-39-4 (E)-2'-hydroxy-4-chlorochalcone 
• 43016-14-4 4-chloro-2'-hydroxychalcone dibromide 
• 873-73-4 4-n-chlorophenylacetylene 
• 1008105-76-7 2-(3-(4-chlorophenyl)-1-hydroxyprop-2-yn-1-yl)phenol 
• 1008105-83-6 (Z)-2-(4-chlorobenzylidene)-2,3-dihydrobenzofuran-3-ol 
• 90-02-8 salicylaldehyde 
• 2142-69-0 2-bromophenyl methyl ketone 
• 1605349-94-7 (2-bromophenyl)(3-(4-chlorophenyl)oxiran-2-yl)methanone 
• 3033-96-3 4-chloro-2'-hydroxychalcone 
• 118-93-4 o-hydroxyacetophenone 
• 1415385-09-9 3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-yn-1-one 
• 77295-59-1 1-chloro-4-(2,2-dibromovinyl)benzene 

Downstream Products

• 590345-67-8 (6RS)-6-(4-Chlorphenyl)-6,12-dihydro-benzofuro[2,3-c][1,5]benzothiazepin 

Relevant academic research and scientific papers

In quest of small-molecules as potent non-competitive inhibitors against influenza

A series of scaffolds namely aurones, 3-indolinones, 4-quinolones and cinnamic acid-piperazine hybrids, was designed, synthesized and investigated in vitro against influenza A/H1N1pdm09 virus. Designed molecules adopted different binding mode i.e., in 430-cavity of neuraminidase, unlike sialic acid and oseltamivir in molecular docking studies. All molecules reduced the viral titer and exhibited non-cytotoxicity along with cryo-protective property towards MDCK cells. Molecules (Z)-2-(3′-Chloro-benzylidene)-1,2-dihydro-indol-3-one (2f), (Z)-2-(4′-Chloro-benzylidene)-1,2-dihydro-indol-3-one (2g) and 2-(2′-Methoxy-phenyl)-1H-quinolin-4-one (3a) were the most interesting molecules identified in this research, endowed with robust potencies showing low-nanomolar EC50 values of 4.0 nM, 6.7 nM and 4.9 nM, respectively, compared to reference competitive and non-competitive inhibitors: oseltamivir (EC50 = 12.7 nM) and quercetin (EC50 = 0.56 μM), respectively. Besides, 2f, 2g and 3a exhibited good neuraminidase inhibitory activity in sub-micromolar range (IC50 = 0.52 μM, 3.5 μM, 1.3 μM respectively). Moreover, these molecules were determined as non-competitive inhibitors similar to reference non-competitive inhibitor quercetin unlike reference competitive inhibitor oseltamivir in kinetics studies.

An unusual triazole synthesis from aurones

Attempts to prepare azido-substituted aurones via a copper-catalyzed azidation failed to afford the desired product, but instead resulted in an unusual triazole formation reaction. Further efforts noted that copper was not required for this reaction, but simply thermal treatment with sodium azide in a polar aprotic solvent. A wide range of substitution patterns were tolerated in this reaction to afford the interesting salicyl-substituted triazoles in modest to excellent yield. While the mechanism is not yet clear, a simple elimination/cyclization pathway seems unlikely given the failure of the reaction on the corresponding thioaurones, which feature an even better thiol leaving group. Regardless, the potential utility of these easily accessible, multifunctional compounds should engender further interest and applications.

Rh-Catalyzed aldehydic C-H alkynylation and annulation

Novel Rh-catalyzed aldehydic C-H bond alkynylation and annulation for the in situ synthesis of chromones and aurones are described. It involves the sequential aldehyde C-H bond alkynylation of salicylaldehyde with in situ generated 1-bromoalkyne from 1,1-

A novel cyclization/oxidation strategy for a two-step synthesis of (Z)-aurone

An efficient and facile two-step strategy for the synthesis of (Z)-aurone from arylacetylenes and salicyladehydes, via silver(I) nitrate mediated cyclization/oxidation in the presence of potassium carbonate has been developed. The key feature of our metho

"On water" synthesis of aurones: First synthesis of 4,5,3',4',5'-pentamethoxy-6-hydroxyaurone from Smilax riparia

A simple and green method for the synthesis of aurones by condensation of benzofuranone with aromatic aldehyde in neat water has been developed. The main advantages of this protocol include good yields, absence of catalyst, reagent, organic solvent, work-up and chromatographic purification. 4,5,3',4',5'-Pentamethoxy-6-hydroxyaurone, isolated from Smilax riparia was synthesized for the first time from 3-benzyloxy-4,5-dimethoxybenzaldehyde in five steps. {figure presented}.

Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease

To develop effective therapeutics for inflammatory bowel disease (IBD), 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives, were designed and synthesized and their structure-activity relationships (SAR) were investigated. Compounds 7, 25, 26, 32, 39, 41, 52, 54, and 55 showed potent inhibitory effect (>70%) on the TNF-α-induced adhesion of monocytes to colon epithelial cells, which is one of the hallmark events leading to IBD. Such inhibitory activity of the compounds correlated with their suppressive activities against the TNF-α-induced production of ROS; ICAM-1 and MCP-1 expression, critical molecules involved in monocyte-epithelial adhesion; and NF-κB transcriptional activity. In addition, compounds 41 and 55 significantly suppressed the lipopolysaccharide (LPS)-induced expression of the TNF-α gene, with compound 55 showing better efficacy. This inhibition of TNF-α expression by compounds 41 and 55 corresponded to their additional inhibitory activity against AP-1 transcriptional activity, which is another transcription factor required for high level TNF-α expression. The strong inhibitory activity of compound 55 against an in vivo colitis model was confirmed by its dose-dependent inhibitory activity in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis, demonstrating compound 55 as a new potential candidate for the development of therapeutics against IBD.

THERAPEUTIC AURONES

Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.

Composition for preventing or treating inflammatory bowel disease comprising benzylidene benzofuranone compound as an active ingredient

The present invention relates to a composition for preventing and treating inflammatory bowel disease comprising a benzylidene benzofuranone derivative compound as an active ingredient. The benzylidene benzofuranone derivative compound is effective in maintaining the thickness of small intestine and the length of large intestine to normal states, and inhibiting inflammation with respect to large intestine, thereby being used as a pharmaceutical composition for preventing and treating inflammatory bowel disease.

An efficient synthesis of aurone derivatives by the tributylphosphine-catalyzed regioselective cyclization of o-alkynoylphenols

An organocatalytic regioselective synthes is of aurones from o-alkynoylphenols was achieved. A catalytic amount of tributylphosphine select ively induced the 5-exo cyclization of o-alkynoylphenols under ambient conditions leading to aurone derivatives in high to excellent yields.

Aurones as histone deacetylase inhibitors: Identification of key features

In this study, a total of 22 flavonoids were tested for their HDAC inhibitory activity using fluorimetric and BRET-based assays. Four aurones were found to be active in both assays and showed IC50 values below 20 μM in the enzymatic assay. Molecular modelling revealed that the presence of hydroxyl groups was responsible for good compound orientation within the isoenzyme catalytic site and zinc chelation.